Treatment of Clostridium difficile-associated disease: Old therapies and new strategies

Lancet Infectious Diseases

Volumn 5, Issue 9, 2005, Pages 549-557

  Aslam, Saima ^a,b   Hamill, Richard J ^a,b   Musher, Daniel M ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BACTERIAL VACCINE; COLESTIPOL; COLESTYRAMINE; DIPHENOXYLATE; IMMUNOGLOBULIN; LIVE VACCINE; LOPERAMIDE; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TIZOXANIDE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FECES LEVEL; ENTEROCOLITIS; HELMINTHIASIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTESTINE FLORA; INTESTINE TRANSIT TIME; LACTOBACILLUS; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; RECURRENT DISEASE; RELAPSE; REVIEW; RIBOTYPING; SACCHAROMYCES BOULARDII; SALMONELLA TYPHIMURIUM; TOXIC MEGACOLON; TREATMENT FAILURE; VIBRIO CHOLERAE;

ANTI-INFECTIVE AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; PROBIOTICS; RECURRENCE; VACCINATION; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 23944507069     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70215-2     Document Type: Review

References (143)

1. LV McFarland Diarrhea acquired in the hospital Gastroenterol Clin North Am 22 1993 563 577
2. JG Bartlett Clostridium difficile: clinical considerations Rev Infect Dis 12 suppl 2 1990 S243 S251
3. JG Bartlett Clinical practice. Antibiotic-associated diarrhea N Engl J Med 346 2002 334 339
4. MM Olson, CJ Shanholtzer, JT Lee Jr., DN Gerding Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991 Infect Control Hosp Epidemiol 15 1994 371 381
5. L Kyne, M Warny, A Qamar, CP Kelly Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea Lancet 357 2001 189 193
6. M Moshkowitz, E Ben Baruch, Z Kline, G Moshe, Z Shimoni, F Konikoff Clinical manifestations and outcome of pseudomembranous colitis in an elderly population in Israel Isr Med Assoc J 6 2004 201 204
7. J Pepin, L Valiquette, ME Alary Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity CMAJ 171 2004 466 472
8. DM Musher, S Aslam, N Logan Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole Clin Infect Dis 40 2005 1586 1590
9. J Pepin, ME Alary, L Valiquette Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada Clin Infect Dis 40 2005 1591 1597
10. L Kyne, MB Hamel, R Polavaram, CP Kelly Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile Clin Infect Dis 34 2002 346 353
11. MH Wilcox, JG Cunniffe, C Trundle, C Redpath Financial burden of hospital-acquired Clostridium difficile infection J Hosp Infect 34 1996 23 30
12. Anon. Antibiotics, staphylococcal enteritis and pseudomembranous enterocolitis N Engl J Med 249 1953 37 40
13. P Lundsgaard-Hansen, A Senn, B Roos, U Waller Staphylococcic enterocolitis. Report of six cases with two fatalities after intravenous administration of N-(pyrrolidinomethyl) tetracycline JAMA 173 1960 1008 1013
14. SE Keidan, IF Sutherland Staphylococcal pseudomembranous enterocolitis Lancet 1 1954 1125 1126
15. E Williams Staphylococcal pseudomembranous enterocolitis complicating treatment with aureomycin Lancet 1 1954 999 1000
16. GH Friedell, E Paige Pseudomembranous enterocolitis following antibiotic therapy for pneumonia: report of a case Am J Clin Pathol 24 1954 1159 1164
17. WF Baden Staphylococcal and subsequent Candida albicans enterocolitis complicating novobiocin therapy Am J Obstet Gynecol 74 1957 47 52
18. FJ Tedesco, RW Barton, DH Alpers Clindamycin-associated colitis. A prospective study Ann Intern Med 81 1974 429 433
19. JG Bartlett, AB Onderdonk, RL Cisneros, DL Kasper Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters J Infect Dis 136 1977 701 705
20. GD Rifkin, FR Fekety, J Silva Jr. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin Lancet 2 1977 1103 1106
21. HE Larson, AB Price Pseudomembranous colitis: presence of clostridial toxin Lancet 2 1977 1312 1314
22. JG Bartlett, TW Chang, M Gurwith, SL Gorbach, AB Onderdonk Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia N Engl J Med 298 1978 531 534
23. JG Bartlett, N Moon, TW Chang, N Taylor, AB Onderdonk Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis Gastroenterology 75 1978 778 782
24. DN Gerding, S Johnson, LR Peterson, ME Mulligan, J Silva Jr. Clostridium difficile-associated diarrhea and colitis Infect Control Hosp Epidemiol 16 1995 459 477
25. Hospital Infection Control Practices Advisory Committee (HICPAC) Recommendations for preventing the spread of vancomycin resistance Infect Control Hosp Epidemiol 16 1995 105 113
26. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease Am J Health Syst Pharm 55 1998 1407 1411
27. R Fekety Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis Am J Gastroenterol 92 1997 American College of Gastroenterology, Practice Parameters Committee 739 750
28. Layton BA, McDonald LC, Gerding DN, Liedtke LA, Strausbaugh LJ. Changing patterns of Clostridium difficile disease: a report from infectious disease physicians. 42nd Annual Meeting of the Infectious Disease Society of America, Boston, Sept 30-Oct 3, 2004. Abstract 563
29. E Bricker, R Garg, R Nelson, A Loza, T Novak, J Hansen Antibiotic treatment for Clostridium difficile-associated diarrhea in adults Cochrane Database Syst Rev 1 2005 CD004610
30. IC Hall, E O'Toole Intestinal flora in new-born infants with a description of a new pathogenic anaerobe: Bacillus difficilis Am J Dis Child 48 1935 390 402
31. G Triadafilopoulos, C Pothoulakis, MJ O'Brien, JT LaMont Differential effects of Clostridium difficile toxins A and B on rabbit ileum Gastroenterology 93 1987 273 279
32. C Pothoulakis, R Sullivan, DA Melnick Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes J Clin Invest 81 1988 1741 1745
33. PD Miller, C Pothoulakis, TR Baeker, JT LaMont, TL Rothstein Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore Cell Immunol 126 1990 155 163
34. MC McEllistrem, RJ Carman, DN Gerding, CW Genheimer, L Zheng A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes Clin Infect Dis 40 2005 265 272
35. R Viscidi, S Willey, JG Bartlett Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations Gastroenterology 81 1981 5 9
36. LV McFarland, ME Mulligan, RY Kwok, WE Stamm Nosocomial acquisition of Clostridium difficile infection N Engl J Med 320 1989 204 210
37. S Johnson, CR Clabots, FV Linn, MM Olson, LR Peterson, DN Gerding Nosocomial Clostridium difficile colonisation and disease Lancet 336 1990 97 100
38. CR Clabots, S Johnson, MM Olson, LR Peterson, DN Gerding Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection J Infect Dis 166 1992 561 567
39. TV Riley, M Cooper, B Bell, CL Golledge Community-acquired Clostridium difficile-associated diarrhea Clin Infect Dis 20 suppl 2 1995 S263 S265
40. LR Hirschhorn, Y Trnka, A Onderdonk, ML Lee, R Platt Epidemiology of community-acquired Clostridium difficile-associated diarrhea J Infect Dis 169 1994 127 133
41. S Johnson, DN Gerding Clostridium difficile-associated diarrhea Clin Infect Dis 26 1998 1027 1034
42. L Kyne, S Sougioultzis, LV McFarland, CP Kelly Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea Infect Control Hosp Epidemiol 23 2002 653 659
43. ME Mulligan, SD Miller, LV McFarland, HC Fung, RY Kwok Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile Clin Infect Dis 16 suppl 4 1993 S239 S244
44. L Kyne, M Warny, A Qamar, CP Kelly Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A N Engl J Med 342 2000 390 397
45. JK Shim, S Johnson, MH Samore, DZ Bliss, DN Gerding Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea Lancet 351 1998 633 636
46. M Warny, JP Vaerman, V Avesani, M Delmee Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection Infect Immun 62 1994 384 389
47. DG Teasley, DN Gerding, MM Olson Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis Lancet 2 1983 1043 1046
48. JG Bartlett Treatment of antibiotic-associated pseudomembranous colitis Rev Infect Dis 6 suppl 1 1984 S235 S241
49. S Nair, D Yadav, M Corpuz, CS Pitchumoni Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation Am J Gastroenterol 93 1998 1873 1876
50. JF Wallace, RH Smith, RG Petersdorf Oral administration of vancomycin in the treatment of staphylococcal enterocolitis N Engl J Med 272 1965 1014 1015
51. MY Khan, WH Hall Staphylococcal enterocolitis: treatment with oral vancomycin Ann Intern Med 65 1966 1 8
52. F Tedesco, R Markham, M Gurwith, D Christie, JG Bartlett Oral vancomycin for antibiotic-associated pseudomembranous colitis Lancet 2 1978 226 228
53. J Silva Jr., DH Batts, R Fekety, JF Plouffe, GD Rifkin, I Baird Treatment of Clostridium difficile colitis and diarrhea with vancomycin Am J Med 71 1981 815 822
54. R Fekety, J Silva, B Buggy, HG Deery Treatment of antibiotic-associated colitis with vancomycin J Antimicrob Chemother 14 suppl D 1984 97 102
55. R Fekety, J Silva, C Kauffman, B Buggy, HG Deery Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens Am J Med 86 1989 15 19
56. GP Young, PB Ward, N Bayley Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin Gastroenterology 89 1985 1038 1045
57. MN Dudley, JC McLaughlin, G Carrington, J Frick, CH Nightingale, R Quintiliani Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial Arch Intern Med 146 1986 1101 1104
58. F de Lalla, R Nicolin, E Rinaldi Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea Antimicrob Agents Chemother 36 1992 2192 2196
59. RD Cherry, D Portnoy, M Jabbari, DS Daly, DG Kinnear, CA Goresky Metronidazole: an alternate therapy for antibiotic-associated colitis Gastroenterology 82 1982 849 851
60. C Wenisch, B Parschalk, M Hasenhundl, AM Hirschl, W Graninger Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea Clin Infect Dis 22 1996 813 818
61. A Fernandez, G Anand, F Friedenberg Factors associated with failure of metronidazole in Clostridium difficile-associated disease J Clin Gastroenterol 38 2004 414 418
62. JG Bartlett, FJ Tedesco, S Shull, B Lowe, T Chang Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis Gastroenterology 78 1980 431 434
63. F de Lalla, G Privitera, E Rinaldi, G Ortisi, D Santoro, G Rizzardini Treatment of Clostridium difficile-associated disease with teicoplanin Antimicrob Agents Chemother 33 1989 1125 1127
64. LV McFarland, CM Surawicz, RN Greenberg A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease JAMA 271 1994 1913 1918
65. T Noren, T Akerlund, E Back Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county J Clin Microbiol 42 2004 3635 3643
66. J Dzink, JG Bartlett In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis Antimicrob Agents Chemother 17 1980 695 698
67. F Biavasco, E Manso, PE Varaldo In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile Antimicrob Agents Chemother 35 1991 195 197
68. SS Wong, PC Woo, WK Luk, KY Yuen Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E test Diagn Microbiol Infect Dis 34 1999 1 6
69. SH Cheng, FY Chu, SH Lo, JJ Lu Antimicrobial susceptibility of Clostridium difficile by E test J Microbiol Immunol Infect 32 1999 116 120
70. F Barbut, D Decre, B Burghoffer Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997 Antimicrob Agents Chemother 43 1999 2607 2611
71. A Marchese, A Salerno, A Pesce, EA Debbia, GC Schito In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species Chemotherapy 46 2000 253 266
72. WY Jamal, EM Mokaddas, TL Verghese, VO Rotimi In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait Int J Antimicrob Agents 20 2002 270 274
73. T Pelaez, L Alcala, R Alonso, M Rodriguez-Creixems, JM Garcia-Lechuz, E Bouza Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin Antimicrob Agents Chemother 46 2002 1647 1650
74. Subcommittee on Prevention and Control of Antimicrobial-resistant Microorganisms in Hospitals Preventing the spread of vancomycin resistance: report from the Hospital Infection Control Practices Advisory Committee Fed Regist 59 1994 25758 25763
75. DN Gerding Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 25 suppl 2 1997 S206 S210
76. B Olsson-Liljequist, CE Nord In vitro susceptibility of anaerobic bacteria to nitroimidazoles Scand J Infect Dis Suppl 26 1981 42 45
77. JS Brazier, W Fawley, J Freeman, MH Wilcox Reduced susceptibility of Clostridium difficile to metronidazole J Antimicrob Chemother 48 2001 741 742
78. JL Sanchez, DN Gerding, MM Olson, S Johnson Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C. difficile-associated disease treatment failures and successes Anaerobe 5 1999 205 208
79. J Mattila, PT Mannisto, R Mantyla, S Nykanen, U Lamminsivu Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route Antimicrob Agents Chemother 23 1983 721 725
80. S Loft, M Dossing, HE Poulsen Influence of dose and route of administration on disposition of metronidazole and its major metabolites Eur J Clin Pharmacol 30 1986 467 473
81. RP Bolton, MA Culshaw Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile Gut 27 1986 1169 1172
82. F Friedenberg, A Fernandez, V Kaul, P Niami, GM Levine Intravenous metronidazole for the treatment of Clostridium difficile colitis Dis Colon Rectum 44 2001 1176 1180
83. R Guzman, J Kirkpatrick, K Forward, F Lim Failure of parenteral metronidazole in the treatment of pseudomembranous colitis J Infect Dis 158 1988 1146 1147
84. TW Chang, SL Gorbach, JG Bartlett, R Saginur Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin Gastroenterology 78 1980 1584 1586
85. M Wullt, I Odenholt A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea J Antimicrob Chemother 54 2004 211 216
86. JF Rossignol, H Maisonneuve Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections Am J Trop Med Hyg 33 1984 511 512
87. JF Rossignol, H Hidalgo, M Feregrino A double-"blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico Trans R Soc Trop Med Hyg 92 1998 663 666
88. JF Rossignol, A Ayoub, MS Ayers Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide J Infect Dis 184 2001 381 384
89. JF Rossignol, A Ayoub, MS Ayers Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide J Infect Dis 184 2001 103 106
90. CS McVay, RD Rolfe In vitro and in vivo activities of nitazoxanide against Clostridium difficile Antimicrob Agents Chemother 44 2000 2254 2258
91. L Dubreuil, I Houcke, Y Mouton, JF Rossignol In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms Antimicrob Agents Chemother 40 1996 2266 2270
92. J Broekhuysen, A Stockis, RL Lins, J De Graeve, JF Rossignol Nitazoxanide: pharmacokinetics and metabolism in man Int J Clin Pharmacol Ther 38 2000 387 394
93. JL Trudel, M Deschenes, S Mayrand, AN Barkun Toxic megacolon complicating pseudomembranous enterocolitis Dis Colon Rectum 38 1995 1033 1038
94. E Elinav, D Planer, ME Gatt Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis Int J Colorectal Dis 19 2004 273 276
95. J Salcedo, S Keates, C Pothoulakis Intravenous immunoglobulin therapy for severe Clostridium difficile colitis Gut 41 1997 366 370
96. MH Wilcox Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea J Antimicrob Chemother 53 2004 882 884
97. CP Kelly, C Pothoulakis, F Vavva Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins Antimicrob Agents Chemother 40 1996 373 379
98. DM Lyerly, EF Bostwick, SB Binion, TD Wilkins Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate Infect Immun 59 1991 2215 2218
99. Babcock GJ, Coccia JA, Esshaki DJ. Human monoclonal antibody against toxin a protects hamsters from Clostridium difficile disease. 42nd Annual Meeting of the Infectious Disease Society of America, Boston, Sept 30-Oct 3, 2004. Abstract 567
100. JG Bartlett, TW Chang, AB Onderdonk Comparison of five regimens for treatment of experimental clindamycin-associated colitis J Infect Dis 138 1978 81 86
101. GA Mogg, Y Arabi, D Youngs Therapeutic trials of antibiotic associated colitis Scand J Infect Dis Suppl suppl 22 1980 41 45
102. GA Mogg, RH George, D Youngs Randomized controlled trial of colestipol in antibiotic-associated colitis Br J Surg 69 1982 137 139
103. NS Taylor, JG Bartlett Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins J Infect Dis 141 1980 92 97
104. C Cavagnaro, S Berezin, MS Medow Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis Arch Dis Child 88 2003 342 344
105. JC Cozart, SS Kalangi, MH Clench Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment J Clin Gastroenterol 16 1993 192 194
106. SS Lu, JM Schwartz, DM Simon, LJ Brandt Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study Am J Gastroenterol 89 1994 1226 1229
107. R Fekety, LV McFarland, CM Surawicz, RN Greenberg, GW Elmer, ME Mulligan Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial Clin Infect Dis 24 1997 324 333
108. S Johnson, A Adelmann, CR Clabots, LR Peterson, DN Gerding Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism J Infect Dis 159 1989 340 343
109. GL O'Neill, MH Beaman, TV Riley Relapse versus reinfection with Clostridium difficile Epidemiol Infect 107 1991 627 635
110. F Barbut, A Richard, K Hamadi, V Chomette, B Burghoffer, JC Petit Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea J Clin Microbiol 38 2000 2386 2388
111. Y Tang-Feldman, S Mayo, J Silva Jr., SH Cohen Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea J Clin Microbiol 41 2003 3413 3414
112. LV McFarland, GW Elmer, CM Surawicz Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease Am J Gastroenterol 97 2002 1769 1775
113. BP Buggy, R Fekety, J Silva Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin J Clin Gastroenterol 9 1987 155 159
114. SE Persky, LJ Brandt Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope Am J Gastroenterol 95 2000 3283 3285
115. J Aas, CE Gessert, JS Bakken Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube Clin Infect Dis 36 2003 580 585
116. D Seal, SP Borriello, F Barclay, A Welch, M Piper, M Bonnycastle Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain Eur J Clin Microbiol 6 1987 51 53
117. M Pochapin The effect of probiotics on Clostridium difficile diarrhea Am J Gastroenterol 95 suppl 1 2000 S11 S13
118. M Wullt, ML Hagslatt, I Odenholt Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial Scand J Infect Dis 35 2003 365 367
119. S Plummer, MA Weaver, JC Harris, P Dee, J Hunter Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea Int Microbiol 7 2004 59 62
120. AL D'Souza, C Rajkumar, J Cooke, CJ Bulpitt Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis BMJ 324 2002 1361
121. IL Beales Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea Gut 51 2002 456
122. DY Leung, CP Kelly, M Boguniewicz, C Pothoulakis, JT LaMont, A Flores Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin J Pediatr 118 1991 633 637
123. M Delmee, B Vandercam, V Avesani, JL Michaux Epidemiology and prevention of Clostridium difficile infections in a leukemia unit Eur J Clin Microbiol 6 1987 623 627
124. RB Kerr, DI McLaughlin, LW Sonnenberg Control of Clostridium difficile colitis outbreak by treating asymptomatic carriers with metronidazole Am J Infect Control 18 1990 332 335
125. S Johnson, SR Homann, KM Bettin Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial Ann Intern Med 117 1992 297 302
126. AB Zafar, LA Gaydos, WB Furlong, MH Nguyen, PA Mennonna Effectiveness of infection control program in controlling nosocomial Clostridium difficile Am J Infect Control 26 1998 588 593
127. GW Kaatz, SD Gitlin, DR Schaberg Acquisition of Clostridium difficile from the hospital environment Am J Epidemiol 127 1988 1289 1294
128. JL Mayfield, T Leet, J Miller, LM Mundy Environmental control to reduce transmission of Clostridium difficile Clin Infect Dis 31 2000 995 1000
129. MH Wilcox, WN Fawley, N Wigglesworth, P Parnell, P Verity, J Freeman Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection J Hosp Infect 54 2003 109 114
130. SE Brooks, RO Veal, M Kramer, L Dore, N Schupf, M Adachi Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables Infect Control Hosp Epidemiol 13 1992 98 103
131. C McNulty, M Logan, IP Donald Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy J Antimicrob Chemother 40 1997 707 711
132. P Carling, T Fung, A Killion, N Terrin, M Barza Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years Infect Control Hosp Epidemiol 24 2003 699 706
133. SM Pear, TH Williamson, KM Bettin, DN Gerding, JN Galgiani Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use Ann Intern Med 120 1994 272 277
134. MW Climo, DS Israel, ES Wong, D Williams, P Coudron, SM Markowitz Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost Ann Intern Med 128 1998 989 995
135. KA O'Connor, M Kingston, M O'Donovan, B Cryan, C Twomey, D O'Mahony Antibiotic prescribing policy and Clostridium difficile diarrhoea QJM 97 2004 423 429
136. MH Wilcox, J Freeman, W Fawley Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea J Antimicrob Chemother 54 2004 168 172
137. R Khan, J Cheesbrough Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital J Hosp Infect 54 2003 104 108
138. R Gaynes, D Rimland, E Killum Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use Clin Infect Dis 38 2004 640 645
139. JF Torres, DM Lyerly, JE Hill, TP Monath Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters Infect Immun 63 1995 4619 4627
140. ET Ryan, JR Butterton, RN Smith, PA Carroll, TI Crean, SB Calderwood Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain Infect Immun 65 1997 2941 2949
141. SJ Ward, G Douce, D Figueiredo, G Dougan, BW Wren Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A Infect Immun 67 1999 2145 2152
142. D Pavliakova, JS Moncrief, DM Lyerly Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice Infect Immun 68 2000 2161 2166
143. S Aboudola, KL Kotloff, L Kyne Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A Infect Immun 71 2003 1608 1610